Summary:
Would you like to be a part of the future in diabetes research?
The CARMELINA Study is an international clinical research study looking at the impact of an investigational drug called linagliptin on the long-term occurrence of selected complications of cardiovascular disease (e.g. stroke or heart attack) in people with type 2 diabetes mellitus receiving standard of care.
Linagliptin has been approved in many countries throughout the world for the treatment of type 2 diabetes mellitus. It belongs to a group of medicines called oral antidiabetics, which work by helping the body to reduce the level of sugar in the blood.
You may be eligible to participate in the study if:
- you are 18 years of age or older
- you have been diagnosed with type 2 diabetes mellitus
- you have been receiving a stable dose of antidiabetic medication for at least 8 weeks or you have not previously received antidiabetic treatment
- you have previously had problems with your heart (cardiovascular disease) or kidneys (renal disease). Your doctor will be able to confirm this.